BiotechTube
Home/Biomea Fusion/Mick Hitchcock, Ph.D.
MH

Mick Hitchcock, Ph.D.

Interim Chief Executive Officer and Board Member

Biomea Fusion

Therapeutic Areas

DiabetesObesity

Biomea Fusion Pipeline

DrugIndicationPhase
Icovamenib (BMF-219)Type 2 Diabetes (Insulin-Deficient)Phase 2
BMF-650Obesity / Metabolic DiseasePreclinical

Leadership Team at Biomea Fusion

JP
Juan Pablo Frías, M.D.
Chief Medical Officer
RD
Ralph DeFronzo, M.D.
Key Opinion Leader / Scientific Advisor
View full Biomea Fusion profile